Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...
The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when ...
It appears an unintended side effect of the drug has now struck some of Britain's known suitmakers, who are fed up with ...
Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and ...
New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...
Karen Huger revealed whether she's using Ozempic, explaining she's using a medication for a reason other than weight loss. Learn more.
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.
Compounded copycat drugs containing tirzepatide, many sold by online pharmacies, will no longer be allowed. Semaglutide, the main ingredient in Ozempic and Wegovy, is in ongoing shortage ...
A new study found people with type 2 diabetes who used drugs like Ozempic had a reduced risk of 42 health conditions or ...